Yabao Pharmaceutical Group Co Ltd (600351) — Cash Flow Reinvestment Rate
Yabao Pharmaceutical Group Co Ltd (600351) has a Cash Flow Reinvestment Rate of 0.06x as of September 2025, reinvesting CN¥7.58 Million (capex CN¥7.58 Million ) from operating cash flow of CN¥129.49 Million. Check 600351 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Yabao Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate (2001–2024)
Historical reinvestment intensity for Yabao Pharmaceutical Group Co Ltd across 22 annual periods. Explore 600351 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Yabao Pharmaceutical Group Co Ltd (2001–2024)
Year-by-year capital reinvestment analysis for Yabao Pharmaceutical Group Co Ltd. For live market cap and broader valuation context, see 600351 company net worth.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.07x | CN¥34.77 Million | CN¥471.69 Million | CN¥34.66 Million | ▼ -83.9% |
| 2023 | 0.46x | CN¥227.23 Million | CN¥497.55 Million | CN¥99.86 Million | ▲ +32.3% |
| 2022 | 0.35x | CN¥158.96 Million | CN¥460.46 Million | CN¥62.23 Million | ▲ +14.4% |
| 2021 | 0.30x | CN¥132.04 Million | CN¥437.50 Million | CN¥95.05 Million | ▼ -45.6% |
| 2020 | 0.55x | CN¥211.38 Million | CN¥380.96 Million | CN¥62.87 Million | ▲ +25.6% |
| 2019 | 0.44x | CN¥187.75 Million | CN¥425.17 Million | CN¥157.09 Million | ▲ +124.1% |
| 2018 | 0.20x | CN¥84.06 Million | CN¥426.60 Million | CN¥68.01 Million | ▼ -74.1% |
| 2017 | 0.76x | CN¥122.98 Million | CN¥161.73 Million | CN¥99.34 Million | ▲ +21.5% |
| 2016 | 0.63x | CN¥97.61 Million | CN¥155.95 Million | CN¥84.46 Million | ▼ -24.0% |
| 2015 | 0.82x | CN¥118.14 Million | CN¥143.47 Million | CN¥101.68 Million | ▼ -15.4% |
| 2014 | 0.97x | CN¥173.84 Million | CN¥178.63 Million | CN¥173.84 Million | ▼ -44.2% |
| 2013 | 1.74x | CN¥99.02 Million | CN¥56.80 Million | CN¥99.02 Million | ▼ -40.6% |
| 2011 | 2.94x | CN¥119.56 Million | CN¥40.73 Million | CN¥119.56 Million | ▼ -70.9% |
| 2010 | 10.09x | CN¥187.30 Million | CN¥18.57 Million | CN¥187.30 Million | ▲ +1278.1% |
| 2009 | 0.73x | CN¥269.82 Million | CN¥368.56 Million | CN¥269.82 Million | ▼ -48.9% |
| 2008 | 1.43x | CN¥147.56 Million | CN¥102.90 Million | CN¥147.56 Million | ▲ +384.1% |
| 2007 | 0.30x | CN¥31.31 Million | CN¥105.69 Million | CN¥31.31 Million | ▼ -92.1% |
| 2006 | 3.77x | CN¥43.70 Million | CN¥11.59 Million | CN¥43.70 Million | ▼ -8.7% |
| 2005 | 4.13x | CN¥108.95 Million | CN¥26.40 Million | CN¥108.95 Million | ▲ +62.3% |
| 2004 | 2.54x | CN¥202.81 Million | CN¥79.73 Million | CN¥202.81 Million | ▲ +125.7% |
| 2002 | 1.13x | CN¥27.38 Million | CN¥24.29 Million | CN¥27.38 Million | ▲ +15.4% |
| 2001 | 0.98x | CN¥23.04 Million | CN¥23.59 Million | CN¥23.04 Million | — |